Basic | |
---|---|
Market Cap | $2.18M |
Price | $2.45 |
52 Week Range | 0.1815-53.039997 |
Beta | 1.86 |
Margins | |
Gross Profit Margin | 97.07% |
Operating Profit Margin | -1480.04% |
Net Profit Margin | 203.13% |
Valuation (TTM) | |
P/E Ratio | 0.78 |
Price to Sales Ratio | 0.37 |
Price to Book Ratio | -0.11 |
PEG Ratio | 0.01 |
Biotechnology
Healthcare
8
1999-04-19T00:00:00.000Z
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, an anti-alpha-synuclein peptidic inhibitor to treat patients with PD; SLS-008, an orally available antagonist for chemoattractant receptor-homologous molecule for the treatment of chronic inflammation in asthma and pediatric orphan indications; SLS-004 for the treatment of PD; SLS-010, an oral histamine H3A receptor antagonist for narcolepsy and related disorders; and SLS-012, an injectable therapy for post-operative pain management. Seelos Therapeutics, Inc. was incorporated in 1987 and is headquartered in New York, New York.
646 293 2100
300 Park Avenue, New York, NY, 10022, US
0001017491